U.S. Representatives August Pfluger (R) and Greg Landsman (D-OH) have introduced the Biosimilar Red Tape Elimination Act, which aims to cut regulatory hurdles and make affordable medications more accessible across the state.
This bipartisan legislation could provide relief for Texans struggling with high prescription drug prices.
The bill would automatically classify biosimilar drugs, which are lower-cost generic alternatives to expensive biologics, as "interchangeable" with their name-brand counterparts upon FDA approval. Current law requires additional studies before biosimilars are deemed interchangeable, which often delays access and increases costs.
"For far too long, unnecessary barriers and outdated FDA requirements have prevented Americans from accessing a less expensive, generic version of their medication," Pfluger said in a statement. "Our legislation is a simple, commonsense step we can take to ensure Texans keep more of their hard-earned money."
According to Julie Reed, the Executive Director of the Biosimilars Forum, biosimilars have already saved the U.S. healthcare system $56 billion, with potential for $181 billion more in savings over the next five years.
The bill is especially relevant to Texas, where rural and low-income communities face limited access to affordable healthcare. By removing red tape, the legislation could help pharmacists provide lower-cost alternatives more quickly, benefiting Texas families at the pharmacy counter.
"Healthcare needs real reform," Landsman added. "This bill would allow pharmacists to swap high-cost prescriptions for safe and effective alternatives, lowering costs and saving folks real money."
If passed, the bill would streamline drug approvals, boost competition, and ensure Texans have better access to life-saving, cost-effective medications.
